Clinical trial
Safety Study of PPI-1019 in Patients With Mild-Moderate Alzheimer's Disease
NCT00100282 · PRAECIS Pharmaceuticals Inc., Industry · Completed
Key facts
| NCT number | NCT00100282 |
|---|---|
| Title | Safety Study of PPI-1019 in Patients With Mild-Moderate Alzheimer's Disease |
| Official title | Single Dose Escalation Safety Study of PPI-1019 in Patients With Mild-Moderate Alzheimer's Disease |
| Lead sponsor | PRAECIS Pharmaceuticals Inc., Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Alzheimer's Disease |
| Intervention type | Drug |
| Interventions | PPI-1019 (APAN) |
| Enrollment | 125 |
| Start date | May 1, 2003 |
| Completion | Jun 1, 2005 |
| First posted | Dec 28, 2004 |
| Last update posted | Sep 19, 2006 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: